I am pleased to inform you that the Hexima Rights Issue successfully closed last week with an overall take-up through entitlements and oversubscriptions of 65.4%. This result was very encouraging and Hexima is grateful to all shareholders who participated in the offer. The remainder of the shares on offer were subscribed for by the underwriter and sub-underwriters as outlined in the prospectus. Once issue of the new shares is finalised, Hexima will publish a new list of its top 20 shareholders.
This funding provides the necessary capital for Hexima to continue development of its lead onychomycosis drug, HXP124, and progress this drug into human clinical trials. I look forward to updating you on the company’s progress in the coming months.
Nicole van der Weerden